Benign Breast Neoplasm
Associated Genetic Biomarkers
NCI Definition: A non-metastasizing neoplasm arising from the breast parenchyma. 
There is 1 clinical trial for benign breast neoplasm, of which 1 is open and 0 are completed or closed. Of the trial that contains benign breast neoplasm as an inclusion criterion, 1 is phase 2 (1 open).
ER, ERBB2, and HER2 are the most frequent gene inclusion criteria for benign breast neoplasm clinical trials .
Abemaciclib is the most common intervention in benign breast neoplasm clinical trials.
Significant Genes in Benign Breast Neoplasm
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for benign breast neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and benign breast neoplasm as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.